Side Effects, Cost, Dosage of Neulasta (pegfilgrastim) Shot | Kunchok Dolma, PharmD | RxEconsult
Menus

All Health Articles

Neulasta (pegfilgrastim) Side Effects, Cost, Dosage Category: Hematology by - October 9, 2014 | Views: 31608 | Likes: 2 | Comment: 0  

Neulasta (pegfilgrastim) for cancer neutropenia

Brand Name: Neulasta
Generic name: pegfilgrastim

Medication Class: CSF (colony stimulation factor), hematopoetic agent
Similar Drugs: Neupogen (filgrastim), Granix (Tbo-filgrastim), Leukine (sargramostin)
Manufacturer: Amgen Inc.
FDA Approval Date: January 31, 2002

What is Neulasta and its mechanism of action?

Neulasta (pegfilgrastim) is a neupogen (filgrastim) that has been conjugated to polyethylene glycol (PEG). Compared to Neupogen, pegfilgrastim, is metabolized much slower, thus stays in the body longer than filgrastim. Filgrastim is recombinant human G-CSF (granulocyte-stimulating factors). G-CSF is found in the bone marrow and it stimulates the production of neutrophils. Neutrophils are a type of white blood cell (WBC) that is part of the body’s immune system which fights infections. Neulasta binds to a specific receptor on hematopoietic cell (blood forming cell), which will stimulate the production, maturation, and activation of neutrophils.

What is Neulasta used for treating?

A common adverse effect of chemotherapy is neutropenia (a low neutrophil or WBC count). Neulasta is FDA approved for preventing chemotherapy-induced febrile neutropenia in patients with non-myeloid malignancies. Severe neutropenia is defined by American Society of Clinical Oncology as fever > 101o F (38.3o C) sustained for >1 hour and absolute neutrophil count (ANC) <500 cells per microL.

Neulasta is also used during autologous stem cell transplantation to harvest peripheral blood stem cells. This is a non-FDA approved indication.

How effective is Neulasta?

Neulasta was evaluated in three randomized, double-blinded, controlled studies. The primary endpoint of the study was to establish that Neulasta is no less effective than filgrastim by measuring the number of days a patient is in severe neutropenia after chemotherapy. If the difference in the number of days in severe neutropenia (between the filgrastim groups and the Neulasta group) is less than 1 day, then it was considered to have met the efficacy outcome as illustrated in studies one and two below.

In study one, a single subcutaneous injection of Neulasta (6 mg) was compared to filgrastim 5 mcg/kg/day subcutaneous injection. The Neulasta group had an average of 1.8 days of severe neutropenia compared to 1.6 days for the filgrastim group.

In study two, Neulasta 100 mcg/kg/day was compared to filgrastim 5 mcg/kg/day. The Neulasta group had an average of 1.7 days of severe neutropenia compared to 1.6 days for the filgrastim group.

In study three, a single shot of Neulasta (6 mg) was compared to placebo. The placebo group had a higher incidence of febrile neutropenia (1% versus 17%), hospitalization (1% versus 14%) and more intravenous antibiotic (2% versus 10%) were used during treatment.

Continue

 



For More Healthcare Insights Join Us On Twitter
and Facebook. Join The Community To Publish Articles.

Copyright 2019 RxEconsult. All Rights Reserved | Privacy Policy | Terms of Use | Sitemap